G-protein Coupled Receptors Market Size
| Study Period | 2021 - 2029 |
| Market Size (2024) | USD 6.11 Billion |
| Market Size (2029) | USD 8.58 Billion |
| CAGR (2024 - 2029) | 7.01 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
G-protein Coupled Receptors Market Analysis
The Global G-Protein Coupled Receptors Market size is estimated at USD 6.11 billion in 2024, and is expected to reach USD 8.58 billion by 2029, growing at a CAGR of 7.01% during the forecast period (2024-2029).
- The SARS-CoV-2 virus enters the body through the respiratory tract epithelium, mainly the lungs, and spreads to other organs through hematogenous expansion, causing multiorgan injury. The viral vector loading targeting Na+/H+ exchanger regulatory factor 1 (NHERF1) and -arrestin can disrupt the assembly of certain sensory G-protein coupled receptor (GPCR) signalosomes, resulting in disordered cellular responses such as loss of smell and taste.
- This has led researchers to investigate the role of GPCRs in alleviating COVID-19 symptoms. GPCR-targeted drugs have shown potential in reducing the pathogenic symptoms associated with COVID-19, leading to market growth during the initial phase of the pandemic. However, as the pandemic has subsided, research and development activities have slowed down, causing the studied market to lose some traction, but it is expected to have stable growth during the forecast period.
- The G-protein coupled receptors market is anticipated to be driven by the increasing number of cancer cases, cardiovascular infections, and respiratory issues. GPCRs play a crucial role in the development of new medications. According to the American Heart Association's 2021 Journal, more than 130 million adults in the United States are expected to have some type of heart disease by 2035. The Heart and Stroke Foundation of Canada's February 2022 report states that 750,000 people are living with heart failure in Canada, and 100,000 people are diagnosed with this incurable condition each year.
- A press release by Septerna in 2021 mentioned that GPCRs are one of the most prolific drug targets, representing approximately one-third of all approved drugs, and currently extend across all major disease areas. Septerna launched a financing of USD 100 million in January 2022 to advance its emerging pipeline of novel GPCR-targeted drug programs spanning multiple therapeutic areas.
- In April 2021, Tectonic Therapeutic raised USD 80 million in financing to unlock the full potential of GPCR-targeted therapies with biologics. These activities by market players are likely to contribute to market growth over the forecast period. Furthermore, strategic collaborations among market players are expected to boost market growth.
- For example, in December 2022, Sosei Heptares and Eli Lilly launched a drug discovery collaboration to discover, develop, and commercialize small compounds that modify novel G protein-coupled receptor (GPCR) targets related to diabetes and metabolic disorders. In August 2022, Sosei Group Corporation and AbbVie announced a new drug development cooperation and option-to-license agreement to identify, develop, and market small compounds modulating novel G protein-coupled receptor (GPCR) targets linked to neurological illness.
- Despite the market's potential for growth, the high cost involved in maintaining GPCR cell lines and the complexity of the GPCR signaling system may impede market growth.
G-protein Coupled Receptors Market Trends
Oncology by Application Segment is Estimated to Hold a Significant Share of the Market Over Forecast Period
- According to a November 2021 article published by PubMed Central, there are more than 700 genes that make up the G-protein-coupled receptors (GPCRs), which constitute the largest family of cell surface signaling receptors in the human genome. These receptors play a vital role in various physiological functions, including sensory modulations and hormonal responses. Recent research has shown that GPCR signaling affects different aspects of cancer biology, such as invasion, migration, and vascular remodeling. GPCRs are important in many types of cancer, contributing to cancer proliferation, angiogenesis, invasion, and metastasis.
- Another article published in the Journal of Current Opinion in Endocrine and Metabolic Research in February 2021 states that GPCRs regulate cellular functions that mediate cell survival, tumor progression, and metastasis, making them significant contributors to oncogenesis. Hence, the development of GPCR-targeted drugs is a promising novel therapeutic strategy for treating various types of cancers.
- To improve our understanding of tumorigenesis and oncogenesis and to help develop novel anti-cancer therapies, it is crucial to discern how G protein-coupled receptor kinases (GRKs) regulate GPCR activity in cancer cells. As GPCR signaling plays a significant role in tumor growth and metastasis, the oncology segment is expected to show growth over the forecast period. Targeting GPCRs and their signaling circuits for the new era of precision medicine and cancer immunotherapies is the focus of current and future research.
North America is Expected to Hold a Significant Share of the Market Over the Forecast Period
- North America is expected to experience significant growth during the forecast period, driven by the economically advanced and technologically developed countries of the United States, Canada, and Mexico. Increasing government investment in the biotechnology and biopharmaceutical sector is also contributing to the growth of the studied market in the region.
- The burden of chronic diseases, particularly in the cardiovascular and cancer applications, is increasing demand for advanced treatments and therapies, further supporting market growth in North America. In 2022, the American Cancer Society estimated that there would be 1.9 million new cancer cases and 609,360 cancer deaths in the United States alone. Similarly, the Canadian Cancer Statistics 2021 reported that approximately 2 in 5 Canadians will be diagnosed with cancer in their lifetime, and 1 in 4 will die from cancer. In 2021, an estimated 229,200 Canadians were diagnosed with cancer, and 84,600 died from cancer.
- The burden of cancer is driving emerging research and findings for advanced therapies, such as the use of designer receptors exclusively activated by a designer drug (DREADDs), which may support the clinical exploration of novel classes of drugs for the treatment of cancer patients and survivors. Additionally, research from Columbia.
G-protein Coupled Receptors Industry Overview
The G-protein coupled receptors (GPCR) market is moderately competitive, with several companies operating in this space. Despite facing various challenges, several biologics are currently under manufacturing processes. Market players are focusing on expanding their product portfolios by adopting inorganic growth strategies such as acquisitions, mergers, and partnerships. Abcam plc, Becton, Dickinson and Company, PerkinElmer Inc., Merck KGaA, Enzo Biochem Inc. (Enzo Life Sciences Inc.), Danaher (Molecular Devices LLC), Promega Corporation, BioInvenu Inc., and Thermo Fisher Scientific are some of the key market players among others.
G-protein Coupled Receptors Market Leaders
-
Promega Corporation
-
PerkinElmer Inc.
-
Thermo Fisher Scientific
-
Enzo Biochem Inc. (Enzo Life Sciences Inc.)
-
Abcam plc.
*Disclaimer: Major Players sorted in no particular order
G-protein Coupled Receptors Market News
- April 2022: Ono Pharmaceutical Co., Ltd. signed a new collaboration agreement with Domain Therapeutics and Universite de Montreal to discover novel small molecules targeting G-Protein Coupled Receptors (GPCRs) in a metabolic disease area.
- January 2022: Septerna, Inc., raised a Series A financing of USD 100 million to expand the frontier of GPCR-Targeted medicines using the native Complex Platform, which the company is using to overcome historical challenges of reaching the vast untapped potential of GPCR drug targets for several diseases.
G-protein Coupled Receptors Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Demand for GPCR Assays in Drug Discovery Studies
4.2.2 Wide Range Applications of GPCRs in the Treatment for Various Medical Conditions
4.2.3 Increasing Prevalence of Chronic Diseases
4.3 Market Restraints
4.3.1 Challenges with the Purification of GPCRs
4.3.2 Complexity of the GPCR Signalling System
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Assay Type
5.1.1 Calcium Level Detection Assays
5.1.2 Radioligand Binding and GTPγS Functional Assays
5.1.3 cAMP Assays and cGMP Assays
5.1.4 β-Arrestin Functional Assays
5.1.5 Reporter Gene Assays
5.1.6 Other Assay Types
5.2 By Application
5.2.1 Cardiovascular System
5.2.2 Central Nervous System (CNS)
5.2.3 Oncology
5.2.4 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPANY PROFILES AND COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abcam plc
6.1.2 Becton, Dickinson and Company
6.1.3 PerkinElmer Inc.
6.1.4 Merck KGaA
6.1.5 Enzo Biochem Inc. (Enzo Life Sciences Inc.)
6.1.6 Danaher (Molecular Devices LLC)
6.1.7 Promega Corporation
6.1.8 BioInvenu Inc.
6.1.9 Thermo Fisher Scientific
6.1.10 Eurofins Scientific
6.1.11 Addex Therapeutics
6.1.12 HD Biosciences Co., Ltd.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
G-protein Coupled Receptors Industry Segmentation
As per the scope of the report, G-protein coupled receptor (GPCR) is a protein located in the cell membrane that binds extracellular substances and transmits signals from these substances to an intracellular molecule called a G protein (guanine nucleotide-binding protein). GPCRs are found in the cell membranes of a wide range of organisms, including mammals, plants, microorganisms, and invertebrates.
The g-protein coupled receptors (GPCR) market is segmented by assay type (calcium level detection assays, radioligand binding and GTPγS functional assays, cAMP assays and cGMP assays, β-arrestin functional assays, reporter gene assays, and other assay types), application (cardiovascular system, central nervous system (CNS), oncology and others), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally.
The report offers the value (in USD million) for the above segments.
| By Assay Type | |
| Calcium Level Detection Assays | |
| Radioligand Binding and GTPγS Functional Assays | |
| cAMP Assays and cGMP Assays | |
| β-Arrestin Functional Assays | |
| Reporter Gene Assays | |
| Other Assay Types |
| By Application | |
| Cardiovascular System | |
| Central Nervous System (CNS) | |
| Oncology | |
| Other Applications |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
G-protein Coupled Receptors Market Research FAQs
How big is the Global G-Protein Coupled Receptors (GPCR) Market?
The Global G-Protein Coupled Receptors (GPCR) Market size is expected to reach USD 6.11 billion in 2024 and grow at a CAGR of 7.01% to reach USD 8.58 billion by 2029.
What is the current Global G-Protein Coupled Receptors (GPCR) Market size?
In 2024, the Global G-Protein Coupled Receptors (GPCR) Market size is expected to reach USD 6.11 billion.
Who are the key players in Global G-Protein Coupled Receptors (GPCR) Market?
Promega Corporation, PerkinElmer Inc., Thermo Fisher Scientific, Enzo Biochem Inc. (Enzo Life Sciences Inc.) and Abcam plc. are the major companies operating in the Global G-Protein Coupled Receptors (GPCR) Market.
Which is the fastest growing region in Global G-Protein Coupled Receptors (GPCR) Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global G-Protein Coupled Receptors (GPCR) Market?
In 2024, the North America accounts for the largest market share in Global G-Protein Coupled Receptors (GPCR) Market.
What years does this Global G-Protein Coupled Receptors (GPCR) Market cover, and what was the market size in 2023?
In 2023, the Global G-Protein Coupled Receptors (GPCR) Market size was estimated at USD 5.71 billion. The report covers the Global G-Protein Coupled Receptors (GPCR) Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Global G-Protein Coupled Receptors (GPCR) Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
G-protein Coupled Receptors Industry Report
Statistics for the 2024 G-protein Coupled Receptors market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. G-protein Coupled Receptors analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
